Compare Caterpillar Inc (CAT) vs TG Therapeutics Inc (TGTX) Price & Performance

Caterpillar (CAT) trades at $837.58, down 0.55% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters have consistently beaten EPS estimates, with Q2 2026 EPS of $8.17 surpassing the $6.22 expectation. Revenue growth is supported by AI data center demand, contributing to a robust $67.59B in 2025 revenue. The stock is near key support at $831, with resistance at $850.

Outlook remains positive due to strong earnings momentum and AI-driven infrastructure demand, though elevated valuation ratios (P/E of 36.32) pose a risk. Analyst consensus is bullish with a $1,010 price target, but investors should monitor macroeconomic pressures and competitive threats. The dividend history and cash flow stability add defensive appeal.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.